{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:48:39Z","timestamp":1777420119582,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Over the past 2 years of the several strategies recommended to help fight COVID-19, nirmatrelvir\/ritonavir is a novel drug shown in the EPIC-HR phase 2 to 3 clinical trial to lower COVID-19-related death or hospitalization at day 28 when compared with placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Our study\u2019s aim was to explore the reported adverse events (AEs) associated with nirmatrelvir\/ritonavir use for COVID-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis using the FDA Adverse Event Reporting System (FAERS) database for AEs, listing nirmatrelvir\/ritonavir as the primary drug between January and June 2022. The primary outcome was the incidence of reported AEs associated with nirmatrelvir\/ritonavir. The OpenFDA database was queried using Python 3.10 to collect the AEs and Stata 17 was used to analyze the database. Adverse events were analyzed by associated medication, with \u201cCovid-19\u201d excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 8098 reports were identified between January and June 2022. Most reported complaints in the AE system were COVID-19 and disease recurrence. The most common symptomatic AEs were dysgeusia, diarrhea, cough, fatigue, and headache. Event rates significantly rose between April and May. Disease recurrence and dysgeusia were the most commonly reported complaints for the top 8 concomitant drugs identified. Cardiac arrest, tremor, akathisia, and death were reported in 1, 3, 67, and 5 cases, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance:<\/jats:title>\n                    <jats:p>This is the first retrospective study done on reported AEs associated with nirmatrelvir\/ritonavir use for COVID-19. COVID-19 and disease recurrence were the most reported AEs. Further monitoring of the FAERS database is warranted to periodically reassess the safety profile of this medication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280231169256","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T07:30:51Z","timestamp":1683271851000},"page":"105-109","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Adverse Events of SARS-CoV-2 Therapy: A Pharmacovigilance Study of the FAERS Database"],"prefix":"10.1177","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6315-0186","authenticated-orcid":false,"given":"Viraaj","family":"Pannu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Jersey Shore University Medical Center, Neptune City, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ndausung","family":"Udongwo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jersey Shore University Medical Center, Neptune City, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Imburgio","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jersey Shore University Medical Center, Neptune City, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anmol","family":"Johal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jersey Shore University Medical Center, Neptune City, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Mararenko","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jersey Shore University Medical Center, Neptune City, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Pozdniakova","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jersey Shore University Medical Center, Neptune City, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tasnuva","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jersey Shore University Medical Center, Neptune City, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swapnil","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jersey Shore University Medical Center, Neptune City, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Hossain","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jersey Shore University Medical Center, Neptune City, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arman","family":"Mushtaq","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jersey Shore University Medical Center, Neptune City, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Jersey Shore University Medical Center, Neptune City, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose M.","family":"Fune","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Jersey Shore University Medical Center, Neptune City, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Heaton","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jersey Shore University Medical Center, Neptune City, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"bibr1-10600280231169256","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3303"},{"key":"bibr2-10600280231169256","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-020-01760-4"},{"key":"bibr3-10600280231169256","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab007"},{"key":"bibr4-10600280231169256","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1744305"},{"key":"bibr5-10600280231169256","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.7257"},{"key":"bibr6-10600280231169256","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01692-5"},{"key":"bibr7-10600280231169256","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2022.128629"},{"key":"bibr8-10600280231169256","unstructured":"Lam C, Patel P. Nirmatrelvir\/Ritonavir. StatPearls Publishing; 2022. Accessed August 18, 2022. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK585126\/"},{"key":"bibr9-10600280231169256","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118542"},{"key":"bibr10-10600280231169256","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac443"},{"key":"bibr11-10600280231169256","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2022.6834"},{"key":"bibr12-10600280231169256","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury\n                      . Paxlovid. National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Accessed January 31, 2022. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK577815\/"},{"key":"bibr13-10600280231169256","doi-asserted-by":"publisher","DOI":"10.1002\/psb.1979"},{"key":"bibr14-10600280231169256","unstructured":"Fact sheet for healthcare providers: emergency use authorization for paxlovid, September 2022. https:\/\/www.fda.gov\/media\/155050\/download"},{"key":"bibr15-10600280231169256","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2022.08.012"},{"key":"bibr16-10600280231169256","volume-title":"Python Tutorial","author":"van Rossum G","year":"1995"},{"key":"bibr17-10600280231169256","volume-title":"Stata Statistical Software: Release 17","author":"StataCorp","year":"2021"},{"key":"bibr18-10600280231169256","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.935952"},{"key":"bibr19-10600280231169256","unstructured":"Food and Drug Administration. Coronavirus (covid-19) update: FDA authorizes pharmacists to prescribe paxlovid with certain limitations. July 6, 2022. www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-pharmacists-prescribe-paxlovid-certain-limitations"},{"key":"bibr20-10600280231169256","doi-asserted-by":"publisher","DOI":"10.1101\/2022.06.21.22276724"},{"key":"bibr21-10600280231169256","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2034936"},{"key":"bibr22-10600280231169256","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2646."},{"key":"bibr23-10600280231169256","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2687PMC9349724"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231169256","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280231169256","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280231169256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:09Z","timestamp":1777374789000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/10600280231169256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1177\/10600280231169256"],"URL":"https:\/\/doi.org\/10.1177\/10600280231169256","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]}}}